Biopharmaceutical company Catabasis Pharmaceuticals Inc (NASDAQ:CATB) said on Wednesday that it has priced its public offering of an aggregate of 4,000,000 units at a public offering price of USD5.00 per unit.
Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock from the company for a total of 4,000,000 shares of common stock and warrants to purchase 2,000,000 shares of common stock. Each warrant will have an exercise price of USD6.25 per share and is exercisable immediately. The warrants will expire five years from the date of issuance.
Prior to deducting the underwriting discount and other estimated offering expenses, the company expects gross proceeds of the offering of approximately USD20.0m.
Net proceeds may be used by the company for clinical trial and research and development activities, continued growth of its manufacturing capabilities, initial investments in commercial and medical affairs infrastructure to support its transition to a commercial-stage company, working capital as well as other general corporate purposes.
Oppenheimer & Co Inc is acting as sole underwriter for the offering. The offering is expected to close on or about 8 February 2019, subject to closing conditions.
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001